For all these reasons, we designed the present study to deeply investigate MGMT, MLH1, CDKN2A, and RASSF1A methylation levels in a cohort of Caucasian TAMG samples large enough to evaluate the contribution of tumor stage and histology, as well as those of the MG clinical subtypes, to the observed findings. The gene discussed is MGMT; the disease is myasthenia gravis.